The trial is projected to enroll approximately 100 adult patients at 20 sites in the US. The study will evaluate the safety and efficacy of PZ-601 in patients with infections including cellulitis, abscesses, infected wounds and ulcers.
Clarence Young, chief medical officer of Protez, said: “Feedback from clinical experts indicates that PZ-601 has the potential to combat infections that represent a significant health risk to patients across the globe, such as infections due to methicillin-resistant Staphylococcus aureus (MRSA) and multidrug- resistant Gram negative organisms.”